Nabriva Therapeutics PLC

Nabriva Therapeutics PLC is a commercial-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative anti-infective agents designed to treat serious infections. The company’s portfolio includes notable products such as XENLETA, a semi-synthetic pleuromutilin antibiotic available in both oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia, and SIVEXTRO, an oxazolidinone-class antibiotic used for acute bacterial skin and skin structure infections. In addition, the pipeline features candidates like CONTEPO, targeting complicated urinary tract infections, and BC-7013, intended for topical treatment of gram-positive infections. Headquartered in Dublin, Ireland, Nabriva Therapeutics operates across the United States, Austria, and Ireland. The company is recognized for its scientific expertise in combating bacterial resistance and its collaborative approach in seeking partnerships to advance solutions for infectious diseases, addressing an urgent and growing global health need.